Adverse effect profile of trichlormethiazide: A retrospective observational study

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Takahashi, Yasuo ^a   Nishida, Yayoi ^a   Nakayama, Tomohiro ^a   Asai, Satoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL MUSCLE RELAXANT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELECTROLYTE; HYPERGLYCEMIC AGENT; POTASSIUM; SODIUM; STEROID; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE; URIC ACID; VASODILATOR AGENT; BIOLOGICAL MARKER; CREATINE; DIURETIC AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; ELECTROLYTE BLOOD LEVEL; FEMALE; GOUT; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POTASSIUM BLOOD LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SODIUM BLOOD LEVEL; THYROID DISEASE; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; DOSE RESPONSE; HYPERURICEMIA; HYPOKALEMIA; JAPAN; MIDDLE AGED; PROPENSITY SCORE; RISK ASSESSMENT; STATISTICAL MODEL; TIME;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; CHI-SQUARE DISTRIBUTION; CREATINE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; POTASSIUM; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SODIUM; TIME FACTORS; TRICHLORMETHIAZIDE; URIC ACID;

EID: 79956207910     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-45     Document Type: Article

References (29)

1. Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents. J Am Med Assoc 1958, 166:137-140.
2. Moser M, Macaulay AI. Chlorothiazide as an adjunct in the treatment of essential hypertension. Am J Cardiol 1959, 3:214-219. 10.1016/0002-9149(59)90289-9, 13626851.
3. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991, 265:3255-3264.
4. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. 10.1001/jama.288.23.2981, 12479763.
5. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011, 57(4):689-694. 10.1161/HYPERTENSIONAHA.110.161505, 21383313.
6. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009, 361:2153-2164. 10.1056/NEJMra0907219, 19940300.
7. Grimm RH, Grandits GA, Cutler JA, Stewart AL, McDonald RH, Svendsen K, Prineas RJ, Liebson PR. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997, 157:638-648. 10.1001/archinte.157.6.638, 9080918.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252. 10.1161/01.HYP.0000107251.49515.c2, 14656957.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187. 10.1097/HJH.0b013e3281fc975a, 17563527.
10. Murai K, Obara T, Ohkubo T, Metoki H, Oikawa T, Inoue R, Komai R, Horikawa T, Asayama K, Kikuya M, et al. Current usage of diuretics among hypertensive patients in Japan: the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res 2006, 29:857-863. 10.1291/hypres.29.857, 17345785.
11. Austin PC, Chiu M, Ko DT, Goeree R, Tu JV. Propensity Score Matching for Estimating Treatment Effects. Analysis of Observational Health Care Data Using SAS 2010, 51-84. Obenchain RL: Cary: SAS Press, Faries DE, Leon AC, Haro JM.
12. Kosanke J, Bergstralh E. GMATCH macro for SAS. Accessed FEB 1, 2011., http://mayoresearch.mayo.edu/mayo/research/biostat/upload/gmatch.sas
13. Austin PC. The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 2008, 61:537-545. 10.1016/j.jclinepi.2007.07.011, 18471657.
14. Neff KM, Nawarskas JJ. Hydrochlorothiazide versus chlorthalidone in the management of hypertension. Cardiol Rev 2010, 18:51-56. 10.1097/CRD.0b013e3181c61b52, 20010338.
15. Kaplan NM. Treatment of hypertension: drug therapy. Clinical Hypertension 2006, 213-310. Philadelphia, PA: Lippincott Williams & Wilkins, Kaplan NM, 9.
16. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review. Cardiovasc Diabetol 2009, 8:18. 10.1186/1475-2840-8-18, 2669450, 19327149.
17. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000, 35:1025-1030.
18. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension 1999, 34:1129-1133.
19. Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009, 32:962-968. 10.1038/hr.2009.133, 19696778.
20. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metab Syndr 2010, 2:44. 10.1186/1758-5996-2-44, 2901246, 20576135.
21. Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gleim GW, Oparil S. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005, 5:17-22. 10.2165/00129784-200505010-00003, 15631534.
22. Izzo JL, Neutel JM, Silfani T, Dubiel R, Walker F. Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens (Greenwich) 2007, 9:45-48.
23. Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol 2006, 61:87-95. 10.1111/j.1365-2125.2005.02531.x, 1884982, 16390355.
24. Elliott WJ, Weber RR, Murphy MB. A double-blind, randomized, placebo-controlled comparison of the metabolic effects of low-dose hydrochlorothiazide and indapamide. J Clin Pharmacol 1991, 31:751-757.
25. Chow KM, Szeto CC, Wong TY, Leung CB, Li PK. Risk factors for thiazide-induced hyponatraemia. QJM 2003, 96:911-917. 10.1093/qjmed/hcg157, 14631057.
26. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000, 342:1887-1892. 10.1056/NEJM200006223422507, 1557642, 10861325.
27. Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. Value Health 2009, 12:1053-1061. 10.1111/j.1524-4733.2009.00601.x, 19744292.
28. Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S. Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 2010, 9:38. 10.1186/1475-2840-9-38, 2933671, 20712859.
29. Kitamura N, Takahashi Y, Yamadate S, Asai S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 2007, 6:26. 10.1186/1475-2840-6-26, 2098751, 17903269.